Randomized, Open Label, Phase 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Pegargiminase (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms TACE
- Sponsors Polaris Pharmaceuticals
- 17 Aug 2017 Status changed from active, no longer recruiting to completed.
- 07 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 07 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2017.